Paul Tudor Jones's ENTA Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 0 shares of Enanta Pharmaceuticals, Inc. (ENTA) worth $0, representing 0.00% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 31 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in ENTA, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2020, adding 44,086 shares. Largest reduction occurred in Q3 2021, reducing 43,479 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Enanta Pharmaceuticals (ENTA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Enanta Pharmaceuticals (ENTA) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -10,381 | Sold Out | 0 | $0.00 |
| Q1 2026 | +10,381 | New Buy | 10,381 | $12.63 |
| Q4 2025 | -10,443 | Sold Out | 0 | $0.00 |
| Q3 2025 | +10,443 | New Buy | 10,443 | $11.97 |
| Q2 2025 | -10,347 | Sold Out | 0 | $0.00 |
| Q4 2024 | -2 | Reduce 0.02% | 10,347 | $5.75 |
| Q3 2024 | +10,349 | New Buy | 10,349 | $10.36 |
| Q2 2024 | -10,405 | Sold Out | 0 | $0.00 |
| Q1 2024 | +10,405 | New Buy | 10,405 | $17.46 |
| Q3 2023 | -10,365 | Sold Out | 0 | $0.00 |
| Q2 2023 | +10,365 | New Buy | 10,365 | $21.40 |
| Q4 2022 | -10,327 | Sold Out | 0 | $0.00 |
| Q3 2022 | -1,659 | Reduce 13.84% | 10,327 | $51.90 |
| Q2 2022 | -17,268 | Reduce 59.03% | 11,986 | $47.31 |
| Q1 2022 | +2,308 | Add 8.57% | 29,254 | $71.17 |
| Q4 2021 | +19,049 | Add 241.22% | 26,946 | $74.78 |
| Q3 2021 | -43,479 | Reduce 84.63% | 7,897 | $56.86 |
| Q2 2021 | +31,365 | Add 156.74% | 51,376 | $44.01 |
| Q1 2021 | -24,075 | Reduce 54.61% | 20,011 | $49.32 |
| Q4 2020 | +44,086 | New Buy | 44,086 | $42.10 |
| Q3 2020 | -11,227 | Sold Out | 0 | $0.00 |
| Q2 2020 | +11,227 | New Buy | 11,227 | $50.24 |
| Q3 2017 | -5,802 | Sold Out | 0 | $0.00 |
| Q2 2017 | -6,100 | Reduce 51.25% | 5,802 | $36.02 |
| Q1 2017 | -3,568 | Reduce 23.06% | 11,902 | $30.84 |
| Q4 2016 | +15,470 | New Buy | 15,470 | $33.48 |
| Q2 2015 | -9,800 | Sold Out | 0 | $0.00 |
| Q1 2015 | +813 | Add 9.05% | 9,800 | $30.61 |
| Q4 2014 | -11,609 | Reduce 56.37% | 8,987 | $50.85 |
| Q3 2014 | +20,596 | New Buy | 20,596 | $39.57 |
Paul Tudor Jones's Enanta Pharmaceuticals Investment FAQs
Paul Tudor Jones first purchased Enanta Pharmaceuticals, Inc. (ENTA) in Q3 2014, acquiring 20,596 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Enanta Pharmaceuticals, Inc. (ENTA) for 31 quarters since Q3 2014.
Paul Tudor Jones's largest addition to Enanta Pharmaceuticals, Inc. (ENTA) was in Q4 2020, adding 44,086 shares worth $1.86 M.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 0 shares of Enanta Pharmaceuticals, Inc. (ENTA), valued at approximately $0.
As of the Q2 2026 filing, Enanta Pharmaceuticals, Inc. (ENTA) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Enanta Pharmaceuticals, Inc. (ENTA) was 51,376 shares, as reported at the end of Q2 2021.